Conexiant’s news site is now MDSpire News. Learn more
Advertisement
FDA updates PAH label with trial data
In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.
To update the sotatercept-csrk (Winrevair) label based on efficacy and safety data from the phase 3 HYPERION trial in adults with pulmonary arterial hypertension.
Approach:
Trial Design: The HYPERION trial was a global, double-blind, placebo-controlled study involving 320 adults diagnosed with pulmonary arterial hypertension. The trial was stopped early based on positive interim results.
Key Findings:
A first clinical worsening event occurred in 11% of patients receiving sotatercept compared to 37% receiving placebo.
Sotatercept reduced the risk of clinical worsening events by 76% compared to placebo.
Safety findings were consistent with previous studies, with common adverse reactions including epistaxis (32% vs 7%) and telangiectasia (26% vs 11%).
Adverse events led to treatment discontinuation in 3% of patients receiving sotatercept, most commonly due to epistaxis.
Interpretation:
The updated label includes additional safety information regarding serious hypersensitivity reactions and contraindications for patients with serious hypersensitivity to sotatercept-csrk or its excipients.
Limitations:
The trial was stopped early based on positive interim results, which may affect the robustness of the findings.
Conclusion:
Sotatercept demonstrates significant efficacy in reducing clinical worsening events in adults with pulmonary arterial hypertension, as evidenced by the trial results.
Incidental pulmonary embolism detection increased following AI deployment on routine contrast-enhanced CT, with the clearest increase occurring in segmental emboli.
Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
